Trove
Sign In Sign Up
You need to sign in or sign up before continuing.

Merck & Co., Inc.

Organization
Mentions
6
Relationships
0
Events
0
Documents
3
Also known as:
Merck
Search

Relationship Network

Loading... nodes
Interactive Network: Click nodes or edges to highlight connections and view details with action buttons. Drag nodes to reposition. Node size indicates connection count. Line color shows relationship strength: red (8-10), orange (6-7), yellow (4-5), gray (weak). Use legend and help buttons in the graph for more guidance.
No relationships found for this entity.
No events found for this entity.

HOUSE_OVERSIGHT_023088.jpg

This document is a page from a Bank of America Merrill Lynch equity strategy report dated January 29, 2017. It contains two tables analyzing S&P 500 companies: one listing companies with high effective tax rates and low foreign sales, and another listing companies likely to benefit from repatriation due to high overseas cash reserves (e.g., Apple, Microsoft, Cisco). The document bears a 'HOUSE_OVERSIGHT_023088' stamp, indicating it was produced as evidence for the House Oversight Committee, though the text itself contains no direct references to Jeffrey Epstein or his associates.

Financial research report (equity strategy)
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024046.jpg

This document appears to be page 35 of a confidential investment memorandum for a fund named NLV-III (likely New Leaf Venture Partners). It outlines the fund's track record with previous investments (NLV-II) in companies like Array, Acadia, and Intercept Pharmaceuticals, highlighting successful exit multiples. The text details the investment thesis for NLV-III, focusing on targeted biopharmaceutical therapies and biomarker-guided programs that benefit patients, physicians, payers, and pharmaceutical companies. The document bears a House Oversight Committee stamp.

Investment memorandum / private placement memorandum
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024024.jpg

This document (page 13, Control Number 257) contains professional biographies for James Niedel and Liam Ratcliffe, executives at New Leaf Venture Partners. It details their educational backgrounds, board memberships, and extensive history in the pharmaceutical industry (GSK and Pfizer respectively), including specific successful drug developments and corporate acquisitions. The document is marked confidential and bears a House Oversight file stamp.

Corporate profile / investment team bio / house oversight document
2025-11-19
Analysis Source
Total Received
$0.00
0 transactions
Total Paid
$0.00
0 transactions
Net Flow
$0.00
0 total transactions
No financial transactions found for this entity. Entity linking may need to be improved.
As Sender
0
As Recipient
0
Total
0
No communications found for this entity. Entity linking may need to be improved.

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein entity

Back to Search